Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Alliance Grants

University of Calgary

$20,000.00

Droplet-PCR point-of-care device for rapid detection of SARS-CoV-2 and differentiation from influenza

EF 2022-23

Résumé
The gold standard method for the diagnosis of viral infections is real-time reverse transcription Polymeric Chain Reaction (rRT-PCR). However, almost all rRT-PCR tests need to be done by skilled personnel in the lab setting and with expensive devices, making it far from a point-of-care (PoC) devices to enable remote- and home-based PCR testing. There is a pressing need for the next generation of PCR-based detection assays that not only are able to perform rapid, very accurate, and for PoC and home-based uses for detection of SARS-CoV-2 but also capable of differentiating among different viral and bacterial infections, necessitating the need to better multiplexing and multi-target testing.In the partnership with Accumol in this project, we will use integrated digital droplet microfluidics and microelectronic systems to develop a low-cost, portable, autonomous, and highly accurate droplet PCR (d-PCR) device that can detect SARS-CoV-2 and differentiate it from other viral infections. The deliverable of this project would be to 1) produce functional RNA amplification PoC device-specific to target SARS-CoV-2 RNAs; 2) develop d-PCR protocols useful for selective differentiation of COVID-19 from other viral infections; 3) increase intellectual property in this area and leverage the background patents on distinct categories of IPs, and 4) disseminate technological progress and scientific knowledge through publications in a high-caliber biomedical engineering journal. The d-PCR and detection protocols developed in this project will contribute to implementing new point-of-care testing for rapidly detecting SARS-CoV-2 and differentiate it from other viral infections, addressing the need for Rapid Response to viral infectious disease outbreaks in Canada. One Ph.D. student with a background in biomedical engineering will be trained over the course of the project, directly supported by the requested funding.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
561767-2021
Name nom
Sanati Nezhad, Amir A
Department département
Biomedical Engineering
Organization id
11
Institution établissement
University of Calgary
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2022
Competition year année de concours
2021
Award amount
20000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Installment
inst:2
Partie
1
Nb partie
2
Application title
Droplet-PCR point-of-care device for rapid detection of SARS-CoV-2 and differentiation from influenza
Application summary
The gold standard method for the diagnosis of viral infections is real-time reverse transcription Polymeric Chain Reaction (rRT-PCR). However, almost all rRT-PCR tests need to be done by skilled personnel in the lab setting and with expensive devices, making it far from a point-of-care (PoC) devices to enable remote- and home-based PCR testing. There is a pressing need for the next generation of PCR-based detection assays that not only are able to perform rapid, very accurate, and for PoC and home-based uses for detection of SARS-CoV-2 but also capable of differentiating among different viral and bacterial infections, necessitating the need to better multiplexing and multi-target testing.In the partnership with Accumol in this project, we will use integrated digital droplet microfluidics and microelectronic systems to develop a low-cost, portable, autonomous, and highly accurate droplet PCR (d-PCR) device that can detect SARS-CoV-2 and differentiate it from other viral infections. The deliverable of this project would be to 1) produce functional RNA amplification PoC device-specific to target SARS-CoV-2 RNAs; 2) develop d-PCR protocols useful for selective differentiation of COVID-19 from other viral infections; 3) increase intellectual property in this area and leverage the background patents on distinct categories of IPs, and 4) disseminate technological progress and scientific knowledge through publications in a high-caliber biomedical engineering journal. The d-PCR and detection protocols developed in this project will contribute to implementing new point-of-care testing for rapidly detecting SARS-CoV-2 and differentiate it from other viral infections, addressing the need for Rapid Response to viral infectious disease outbreaks in Canada. One Ph.D. student with a background in biomedical engineering will be trained over the course of the project, directly supported by the requested funding.